Although the prognostic value was not observed, tumors with HER2-low expression exhibited many different clinical characteristics compared to those with HER2-0 expression, including sex, ER expression, histology type, tumor grade and germline mutation. This evidence concerns the gene ERBB2 and neoplasm.